Are these summer drug price increases hot enough to steal the spotlight from rebates?

Ben LinkSeptember 30, 2024NADAC, Medicaid, Generic, Brand drugs, List prices, WAC, Tecfidera, Humira, PBM, FTC, GLP-1, Gardasil, Tepezza, Enbrel, Abrilada, lofena, meloxicam, Diclofenac, propranolol, dexmethylphenidate, lisdexamfetamine, Methylphenidate, mercaptopurine, Quetiapine, Guanfacine, Dextroamphetamine, Paliperidone, trazodone

46brooklyn’s 2024 Midyear Drug Price Changes Report

Ben LinkAugust 30, 2024NADAC, Medicaid, Generic, Brand drugs, List prices, WAC, Xenical, Paxlovid, Revlimid, Xofluza, ZTlido, Annovera, Apretude, Cabenuva, Ilaris, Rhophylac, Opdivo, varenicline, dexmethylphenidate, Buprenorphine-Naloxone, Fluphenazine, Metformin, Quetiapine

Does Pennsylvania have a spread pricing problem?

As drug pricing scrutiny grows, PBM spread pricing of cheap, generic drugs is becoming a hot topic of conversation in states across the country. After the state of Ohio opened the books thanks to an audit from the state auditor, the uncovered $224 million PBM spread now has other states scrambling to see what they are being charged as well. One of those states is Pennsylvania, where their state auditor is trying hard to get the data he needs to see where the money is going in the third largest managed care program in the country. Since there are many folks wondering what’s going on in Pennsylvania, considering the current lack of hard data, we decided to dig into the publicly available data to see if Pennsylvania appears to have the makings of an “Ohio problem.”